NanoViricides, Inc.

NanoViricides' EKC Eye Drug Demonstrates Significant Therapeutic Efficacy in Initial Animal Trials

Published in TB and Outbreaks Week, June 3rd, 2008

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that it has received positive initial results from the animal trials of its drug candidates for the treatment of epidemic keratoconjunctivitis (EKC), a severe viral infection of the eye. Evidence of significant effectiveness was clinically observed in treated infected eyes.

"We were very pleased with the rapid response to treatment, and we had the opportunity to observe the excellent clinical response ourselves," said Eugene Seymour, MD, MPH, CEO of the Company. "The clinical results we observed are far superior to any data reported in the literature," said Anil R. Diwan, PhD, President of the Company.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2008-06-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry